Shorter courses studies: genotype 4

Study included in MSEligible for inclusion in the current SHTAC systematic review of clinical effectiveness?DetailsComments
Ferenci and colleagues (2008)115NoRetrospective analysis of NV15801 (Jensen and colleagues 2006) and NV 15942 (Hadziyannis trial91)

Note: On p. 106 they refer to this as being a Research Report 1023045 data on file, and refer to the clinical trials as NV15801 (Fried and colleagues41) and NV 15942 (Yu and colleagues54). There is some confusion here regarding the identity of the trials
Study was excluded from our review because it is not a randomised comparison of 24 vs 48 weeks. Patients with RVR were treated for 24 weeks, those without were then randomised at weeks 12–48 or 72 weeks. The journal paper presents SVRs for only the 24-week group anyway (ongoing trial)

From: Appendix 3, SHTAC peer review of clinical effectiveness in the manufacturers' submissions of peginterferon and ribavirin for chronic hepatitis C

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.